The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis

被引：10

作者：

Abushamat, Layla A. ^{[1
]}

Shah, Pir Ahmad ^{[2
]}

Eckel, Robert H. ^{[3
]}

Harrison, Stephen A. ^{[4
]}

Barb, Diana ^{[5
]}

机构：

[1] Baylor Coll Med, Dept Med, Sect Cardiovasc Res, Houston, TX USA

[2] Creighton Univ, Gastroenterol & Hepatol, Phoenix, AZ USA

[3] Univ Colorado Anschutz Med Campus, Div Endocrinol Metab & Diabet, Div Cardiol, Aurora, CO USA

[4] Pinnacle Clin Res, San Antonio, TX USA

[5] Univ Florida, Div Endocrinol Diabet & Metab, 1600 SW Archer Rd,Room H-2, Gainesville, FL 32610 USA

来源：

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY | 2024年 / 22卷 / 08期

关键词：

Metabolic Dysfunction-Associated Steatotic Liver Disease; GLP-1; Steatosis; Cirrhosis; NONALCOHOLIC FATTY LIVER; CARDIOVASCULAR OUTCOMES; MITOCHONDRIAL-FUNCTION; FIBROSIS; DISEASE; MECHANISMS; MANAGEMENT; GLP-1; CARE; METAANALYSIS;

D O I：

10.1016/j.cgh.2024.01.032

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 1 in 3-4 - 4 adult individuals and can progress to metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis. Insulin resistance plays a central role in MASLD/MASH pathophysiology with higher rates of MASLD (2 in 3) and MASH with fi brosis (1 in 5) in adults with obesity and diabetes. This review summarizes the role of glucagon-like peptide-1 receptor agonists in treating MASLD/MASH. Although not approved by the Food and Drug Administration for the treatment of MASLD, this class of medication is available to treat obesity and type 2 diabetes and has been shown to reverse steatohepatitis, reduce cardiovascular risk, and is safe to use across the spectrum of MASLD with or without fi brosis.

引用

页码：1565 / 1574

页数：10